Literature DB >> 28635024

A small molecule activator of Nav 1.1 channels increases fast-spiking interneuron excitability and GABAergic transmission in vitro and has anti-convulsive effects in vivo.

Kristen Frederiksen1, Dunguo Lu2, Jinhui Yang2, Henrik Sindal Jensen1, Jesper Frank Bastlund1, Peter Hjørringgaard Larsen1, Henry Liu2, François Crestey1, Kim Dekermendjian1, Lassina Badolo1, Morten Laursen1, Charlotte Hougaard1, Charles Yang2, Niels Svenstrup1, Morten Grunnet1.   

Abstract

Nav 1.1 (SCN1A) channels primarily located in gamma-aminobutyric acid (GABA)ergic fast-spiking interneurons are pivotal for action potential generation and propagation in these neurons. Inappropriate function of fast-spiking interneurons, leading to disinhibition of pyramidal cells and network desynchronization, correlates with decreased cognitive capability. Further, reduced functionality of Nav 1.1 channels is linked to various diseases in the central nervous system. There is, at present, however no subtype selective pharmacological activators of Nav 1.1 channels available for studying pharmacological modulation of interneuron function. In the current study, we identified a small molecule Nav 1.1 activator, 3-amino-5-(4-methoxyphenyl)thiophene-2-carboxamide, named AA43279, and provided an in vitro to in vivo characterization of the compound. In HEK-293 cells expressing human Nav 1.1 channels, AA43279 increased the Nav 1.1-mediated current in a concentration-dependent manner mainly by impairing the fast inactivation kinetics of the channels. In rat hippocampal brain slices, AA43279 increased the firing activity of parvalbumin-expressing, fast-spiking GABAergic interneurons and increased the spontaneous inhibitory post-synaptic currents (sIPSCs) recorded from pyramidal neurons. When tested in vivo, AA43279 had anti-convulsive properties in the maximal electroshock seizure threshold test. AA43279 was tested for off-target effects on 72 different proteins, including Nav 1.2, Nav 1.4, Nav 1.5, Nav 1.6 and Nav 1.7 and exhibited reasonable selectivity. Taken together, AA43279 might constitute a valuable tool compound for revealing biological functions of Nav 1.1 channels.
© 2017 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Entities:  

Keywords:  SCNA1; activators; interneurons; maximal electroshock seizures threshold; slice electrophysiology

Mesh:

Substances:

Year:  2017        PMID: 28635024     DOI: 10.1111/ejn.13626

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  10 in total

Review 1.  Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies.

Authors:  Julia Oyrer; Snezana Maljevic; Ingrid E Scheffer; Samuel F Berkovic; Steven Petrou; Christopher A Reid
Journal:  Pharmacol Rev       Date:  2018-01       Impact factor: 25.468

Review 2.  [Advances on GABAergic interneurons in autism spectrum disorders].

Authors:  Jie Li; Junyu Xu; Jianhong Luo
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-08-25

Review 3.  Progress in Understanding and Treating SCN2A-Mediated Disorders.

Authors:  Stephan J Sanders; Arthur J Campbell; Jeffrey R Cottrell; Rikke S Moller; Florence F Wagner; Angie L Auldridge; Raphael A Bernier; William A Catterall; Wendy K Chung; James R Empfield; Alfred L George; Joerg F Hipp; Omar Khwaja; Evangelos Kiskinis; Dennis Lal; Dheeraj Malhotra; John J Millichap; Thomas S Otis; Steven Petrou; Geoffrey Pitt; Leah F Schust; Cora M Taylor; Jennifer Tjernagel; John E Spiro; Kevin J Bender
Journal:  Trends Neurosci       Date:  2018-04-23       Impact factor: 13.837

Review 4.  Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.

Authors:  Wolfgang Löscher; Heidrun Potschka; Sanjay M Sisodiya; Annamaria Vezzani
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

5.  A Transient Developmental Window of Fast-Spiking Interneuron Dysfunction in a Mouse Model of Dravet Syndrome.

Authors:  Morgana Favero; Nathaniel P Sotuyo; Emily Lopez; Jennifer A Kearney; Ethan M Goldberg
Journal:  J Neurosci       Date:  2018-08-13       Impact factor: 6.167

Review 6.  The origin of NMDA receptor hypofunction in schizophrenia.

Authors:  Kazu Nakazawa; Kiran Sapkota
Journal:  Pharmacol Ther       Date:  2019-10-16       Impact factor: 12.310

7.  NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype and epileptiform activity in a novel zebrafish model for Dravet Syndrome.

Authors:  Wout J Weuring; Sakshi Singh; Linda Volkers; Martin B Rook; Ruben H van 't Slot; Marjolein Bosma; Marco Inserra; Irina Vetter; Nanda M Verhoeven-Duif; Kees P J Braun; Mirko Rivara; Bobby P C Koeleman
Journal:  PLoS One       Date:  2020-03-05       Impact factor: 3.240

Review 8.  Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe.

Authors:  Elena Cardenal-Muñoz; Stéphane Auvin; Vicente Villanueva; J Helen Cross; Sameer M Zuberi; Lieven Lagae; José Ángel Aibar
Journal:  Epilepsia Open       Date:  2021-12-19

9.  Chronic partial TrkB activation reduces seizures and mortality in a mouse model of Dravet syndrome.

Authors:  Feng Gu; Isabel Parada; Tao Yang; Frank M Longo; David A Prince
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-15       Impact factor: 11.205

10.  Novel Quantitative Analyses of Spontaneous Synaptic Events in Cortical Pyramidal Cells Reveal Subtle Parvalbumin-Expressing Interneuron Dysfunction in a Knock-In Mouse Model of Alzheimer's Disease.

Authors:  Lingxuan Chen; Takashi Saito; Takaomi C Saido; Istvan Mody
Journal:  eNeuro       Date:  2018-08-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.